Ken F. Blount,1 William D. Shannon,2 Elena Deych,2 and Courtney Jones,1 1Rebiotix, Roseville, Minnesota; 2BioRankings, St Louis, Missouri Background RBX2660 is an investigational microbiota restoration therapy in phase 3 clinical development for preventing recurrent Clostridioides difficile infections (CDIs). In a randomized, double-blinded placebo-controlled phase 2B trial, RBX2660 was effective at preventing CDI recurrence. The current study was performed to characterize the […]
Journal Articles
Clearance of Vancomycin-Resistant Enterococcus Concomitant With Administration of a Microbiota-based Drug Targeted at Recurrent Clostridium difficile Infection
Erik R. Dubberke,1 Kathleen M. Mullane,2 Dale N. Gerding,3,4 Christine H. Lee,5 Thomas J. Louie,6 Harriet Guthertz,7 and Courtney Jones8 1Department of Medicine,Washington University School of Medicine, St. Louis, Missouri; 2Section of Infectious Diseases and Global Health, University of Chicago Medicine, 3Department of Medicine, Loyola University Chicago Stritch School of Medicine, Maywood, and 4Edward Hines Jr. Veterans Affairs Hospital, Hines, Illinois; 5Department of Medicine, McMaster […]
Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study
Robert Orenstein,1 Erik Dubberke,2 Robert Hardi,3 Arnab Ray,4 Kathleen Mullane,5 Darrell S. Pardi,6 and Mayur S. Ramesh7; for the PUNCH CD Investigatorsa 1Division of Infectious Diseases, Mayo Clinic–Arizona, Phoenix; 2Department of Medicine, Washington University School of Medicine, St. Louis, Missouri; 3Chevy Chase Clinical Research, Capital Digestive Care, Maryland; 4Ochsner Clinic, New Orleans, Louisiana; 5Section of Infectious Diseases and Global Health, University of Chicago Medicine, Illinois; 6Division […]